Commodity Channel Index
|Bid||76.00 x 800|
|Ask||82.18 x 4000|
|Day's Range||76.01 - 78.19|
|52 Week Range||45.11 - 108.36|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||84.20|
Building on its earlier reveal at the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (TXG) today launched its Targeted Gene Expression Solution for single cell and shortly following for spatial genomic research. Targeted Gene Expression gives scientists the ability to focus their research on the cell types and biomarkers that matter most to their research, enabling them to answer biological questions quickly and efficiently. “Our Targeted Gene Expression Solution provides customers the option to progress from unbiased discoveries to more focused research questions by looking at a subset of genes of interest, which can increase sample throughput, streamline data analysis, and reduce sequencing and computational burdens,” said Ben Hindson, Co-founder, President and Chief Scientific Officer of 10x Genomics.
Today, 10x Genomics (TXG) and One Medical (ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom screening, and seamless access to remote and in-person care. 10x Genomics is the first of One Medical’s more than 7,000 employer customers to begin executing a multi-pronged, cohort-based return to the workplace strategy. 10x Genomics added One Medical as a new healthcare benefit for its employees and began offering voluntary SARS-CoV-2 PCR tests to monitor for possible infection.
Ladies and gentlemen, thank you for standing by, and welcome to the 10x Genomics first-quarter 2020 earnings conference call. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2020. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws.
PLEASANTON, Calif., May 11, 2020 -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the quarter ended March 31, 2020. Recent Highlights Revenue of $71.9.
PLEASANTON, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (TXG) today announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference. 10x Genomics’ management is scheduled to present on Wednesday, May 13 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time. 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health.
PLEASANTON, Calif., April 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (TXG) today announced it will report financial results for the first quarter 2020 after market close on Monday, May 11, 2020. 10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. 10x Genomics products have been adopted by researchers around the world including 96 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 700 research papers on discoveries ranging from oncology to immunology and neuroscience.
PLEASANTON, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (TXG), today provided an update on the actions it is taking to focus its business operations to support critical research in response to the coronavirus (COVID-19) pandemic as well as the financial impact. 10x’s products are a critical tool for infectious disease research because they allow the detailed understanding of how the virus impacts infected people, how the immune system is mobilized, which immune cells react to pathogens and many other aspects of the disease and potential therapies. 10x has been designated an essential business that can continue necessary operations during the COVID-19 outbreak.
PLEASANTON, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (TXG) today announced the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. “Kim has been a leader and a pioneer in introducing new technologies into the healthcare system impacting the lives of countless patients during her time at Genomic Health and Genentech,” said Serge Saxonov, co-founder and CEO of 10x Genomics.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
PLEASANTON, Calif., Feb. 25, 2020 -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 40th Annual Cowen Health Care.
PLEASANTON, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (TXG) today announced a broad range of new products at the Advances in Genome Biology and Technology (AGBT) General Meeting, as well as new capabilities for existing products. Today’s announcements further 10x Genomics’ commitment to helping researchers see biology at greater resolution and scale, conduct more simultaneous measurements, and have richer context for their work regardless of the size or location of their labs. The company also announced that its new Chromium Connect system is now shipping.
Futures: Enphase, Amedisys, 10X Genomics, Palomar were earnings movers overnight. Earlier, AMD showed why investors should focus on the best stocks from the best groups.
PLEASANTON, Calif., Feb. 18, 2020 -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the fourth quarter and full year ended December 31, 2019. Recent.
NEW YORK, NY / ACCESSWIRE / February 18, 2020 / 10x Genomics Inc - Ordinary Shares - Class A (NASDAQ:TXG) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held ...
Editor's note: This story has been updated to reflect the FDA's approval Friday of Agile Therapeutics' hormonal contraceptive patch Twirla. Biotech stocks were quiet in the week ending Feb. 14 amid some ...
PLEASANTON, Calif., Feb. 04, 2020 -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2019.
PLEASANTON, Calif., Jan. 07, 2020 -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming 38th Annual J.P. Morgan Healthcare.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
In these waning days of the second decade of the twenty-first century, technologists and investors are beginning to lay the foundations for new, truly transformational technologies that have the potential to reshape entire industries and rewrite the rules of human understanding. It may sound lofty, but new achievements from businesses and research institutions in areas like machine learning, quantum computing and genetic engineering mean that the futures imagined in science fiction are simply becoming science. Investors and entrepreneurs are deploying hundreds of millions of dollars to create the tools that researchers, scientists and industry will use to re-engineer the building blocks of life to perform different functions in agriculture, manufacturing and medicine.
PLEASANTON, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it has begun shipping its Visium Spatial Gene Expression Solution. The Visium Spatial Gene Expression Solution is the first new product to result from 10x Genomics’ acquisition of Sweden’s Spatial Transcriptomics, a pioneer in the emerging field of spatial genomics. This solution builds on the foundation of Spatial Transcriptomics’ earlier product offering, providing researchers with a comprehensive map of where gene activity is occurring in a tissue specimen.
PLEASANTON, Calif., Nov. 07, 2019 -- 10x Genomics, Inc. (Nasdaq: TXG), today reported financial results for the third quarter ended September 30, 2019. Recent Highlights.
PLEASANTON, Calif., Oct. 25, 2019 -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the third quarter 2019 after market close on Thursday,.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 19.) 10X Genomics Inc (NASDAQ: TXG ) (listed its ...